Searchable abstracts of presentations at key conferences in endocrinology

ea0094p302 | Endocrine Cancer and Late Effects | SFEBES2023

Thyroid function in patients receiving immune checkpoint inhibitors: a large real-world cohort study

Kennedy Oliver , Hoong Ho Jan , Monaghan Phillip , Lorigan Paul , Adam Safwaan

Objective: This study aimed to characterise the relationship between immune checkpoint inhibitors (ICIs), which are commonly used to treat cancer, and thyroid dysfunction in terms of the proportions affected, timing of onset, sequalae and risk factors.Design: Retrospective cohort studyMethods: Patients with normal baseline thyroid function who received an ICI were included. Proport...

ea0082p17 | Poster Presentations | SFEEU2022

Brown tumour of the palate heralding a diagnosis of severe primary hyperparathyroidism in a young male

Boughton Charlotte , Lau Eunice , Scott Francis , Kennedy Robert , Basyuni Shadi , Santhanam Vijayarajan , Das Tilak , Fish Brian , Stokes Victoria , Casey Ruth

Case history: An 18 year old male student presented to the dentist with an eight week history of left-sided facial pain and swelling. He was subsequently referred to the maxillofacial team. His only previous medical encounter was for a traumatic right humerus fracture following a roller-skating injury. He took no regular medication. His father died of an unknown malignant process several years previous and family history was otherwise unremarkable. On questioning, the patient ...

ea0059p088 | Diabetes & cardiovascular | SFEBES2018

Assessment of liver imaging in a diabetic population with an abnormal AST-to-platelet-ratio-index (APRI) or Fibrosis-4-score (FIB4)

Ludgate Stephen , Steen Julie , Divilly Patrick , Naimimohasses Sara , Kennedy Carmel , Pazderska Agnieszka , Phelan Niamh , Norris Suzanne , Healy Marie Louise

We conducted a retrospective study examining the prevalence of abnormal liver function tests (LFTs) in a diabetic population attending a tertiary referral centre and APRI and FIB4 scores were also calculated where possible. APRI and FIB4 scores can be used to estimate degree of liver fibrosis. APRI score >1 has 76% sensitivity, 72% specificity for predicting cirrhosis. APRI score >0.7 has 77% sensitivity, 72% specificity for predicting significant fibrosis. A FIB4 scor...

ea0034p9 | Bone | SFEBES2014

Pre-operative localisation studies in primary hyperparathyroidism: concordance with surgical findings and histology

McKeever Edward , Kennedy Robert , Kirk Stephen , Harper Roy , McLaughlin Darren , Mulligan C , Lynch Tom , Majury Clive , McHenry CM

Successful minimally invasive parathyroidectomy for primary hyperparathyroidism depends on accuracy of pre-operative localisation studies. Ultrasound (US) and sestimibi (SM) scanning remain the imaging modalities of choice reserving MRI, CT and PET for patients who have not been cured by previous explorations or for whom other localization techniques are uninformative or discordant. The aim of this study was to review the accuracy of US and SM in the pre-operative localisation...

ea0005p119 | Endocrine Tumours and Neoplasia | BES2003

Hyperparathyroidism-jaw tumour syndrome (HPT-JT) in Romany families from Portugal is due to a founder mutation of parafibromin

Cavaco B , Guerra L , Carvalho D , Bradley K , Harding B , Kennedy A , Santos M , Sobrinho L , Thakker R , Leite V

The hyperparathyroidism-jaw tumour (HPT-JT) syndrome is an autosomal dominant disease characterised by the occurrence of parathyroid tumours, which are often carcinomas, and fibro-osseous tumours of the jaw bones. The HPT-JT gene is on chromosome 1q25 and consists of 17 exons that encode a 531 amino-acid protein, designated PARAFIBROMIN (Nature Genetics, in press). Thirteen heterozygous germline mutations that result in truncated or inactivated forms of PARAFIBROMIN have been ...

ea0086p274 | Reproductive Endocrinology | SFEBES2022

Investigating hormones triggering the onset of sustained lactation (INSIGHT) pilot study

Fry Alexandria , Rostom Hussam , Price Helen , Archer Amy , Hilier Emily , Meng Xin , Elajnaf Taha , Humphrey Robert , Guha Nishan , James Tim , Kennedy Stephen , Hannan Fadil

The onset of human lactation is characterised by increased breast fullness and the start of copious milk secretion. The process, which typically occurs 1-4 days postpartum, is triggered by a decrease in serum progesterone and high prolactin concentrations, although the exact levels are ill-defined. We aim to establish reference intervals for hormones triggering the onset of sustained lactation and understand how breastfeeding influences hormone secretion, so as to improve the ...

ea0070oc4.6 | Pituitary and Neuroendocrinology | ECE2020

Results from the phase 3, randomized, double-blind, placebo-controlled OPTIMAL study of oral octreotide capsules in adult patients with acromegaly

Samson Susan , Nachtigall Lisa , Fleseriu Maria , Gordon Murray , Ludlam William , Patou Gary , Haviv Asi , Molitch Mark E , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Many patients with acromegaly report limitations of long-acting somatostatin receptor ligand (SRL) injections, including ongoing disease symptoms near cycle-end and injection-site pain. Oral octreotide capsules (OOC) may provide an alternative to monthly injections. The phase 3 CHIASMA OPTIMAL study assessed efficacy and safety of OOC in patients with acromegaly controlled on injectable SRLs.Methods: A multinational, randomized, placebo-contr...

ea0070aep577 | Pituitary and Neuroendocrinology | ECE2020

Biochemical control of most patients reverting to injectable long-acting somatostatin receptor ligands is achieved after one dose: Results from the phase 3, randomized, double blind, placebo-controlled optimal study

Fleseriu Maria , Samson Susan , Nachtigall Lisa , Labadzhyan Artak , Elenkova Atanaska , Molitch Mark E , Ludlam William , Patou Gary , Haviv Asi , Biermasz Nienke , Strasburger Christian J , Kennedy Laurence , Melmed Shlomo

Background: Injectable somatostatin receptor ligands (SRLs) are currently the most widely used therapy for acromegaly. Oral octreotide capsules (OOC) are a potential therapy for acromegaly; the safety and efficacy were evaluated in the CHIASMA OPTIMAL pivotal study (Samson et al. ENDO 2020). As reported, mean IGF-I levels of the OOC group were maintained within normal range at end of treatment in all patients. However, some patients may not respond to OOC treatment (2...

ea0005p114 | Endocrine Tumours and Neoplasia | BES2003

Familial isolated primary hyperparathyroidism due to germline multiple endocrine neoplasia Type 1 (MEN1) mutations

Turner J , Pannett A , Kennedy A , Forbes S , Cavaco B , Bassett J , Cianferotti L , Harding B , Shine B , Flinter F , Maidment C , Trembath R , Thakker R

Primary hyperparathyroidism (HPT) is most frequently encountered as a non-familial disorder, but 10% of patients with primary HPT will have a hereditary form, which may occur as an isolated endocrinopathy or as part of a complex tumour syndrome such as multiple endocrine neoplasia type 1 (MEN 1) or type 2 (MEN 2), or the hereditary hyperparathyroidism-jaw tumour syndrome (HPT-JT). Familial isolated hyperparathyroidism (FIHP) is an autosomal dominant disorder characterised by u...

ea0081p170 | Pituitary and Neuroendocrinology | ECE2022

Safety comparison of 40- vs 60- mg/day doses of oral octreotide capsules for treatment of acromegaly in the chiasma optimal trial

L. Samson Susan , Nachtigall Lisa B. , Fleseriu Maria , Molitch Mark E. , Giustina Andrea , Haviv Asi , Biermasz Nienke , Kennedy Laurence , Jensterle Mojca , Manning Patrick , Elenkova Atanaska , Melmed Shlomo , Strasburger Christian J.

Background: Oral octreotide capsules (OOC) are a treatment option for patients with acromegaly in the United States who have previously responded to injectable somatostatin receptor ligands (iSRLs, octreotide or lanreotide). In previous phase 3 studies, the safety of OOC was shown to be consistent with iSRLs, without dose-dependent adverse reactions. In the double-blind, placebo-controlled period (DPC) of the CHIASMA OPTIMAL trial (NCT03252353), patients were randomized to twi...